Dicerna Pharmaceuticals Inc (Dicerna) is a biopharmaceutical company that discovers and develops therapeutics for the treatment of rare inherited diseases and cancers. The company’s lead product DCR-PHXC is used for the treatment of primary hyperoxaluria (PH). It offers RNAi technology platform GalXCTM is an advanced next-generation RNAi-based therapies that is designed to silence disease-driving genes in the liver. Dicerna’s GalXC-based therapies are processed by the Dicer enzyme, which is the natural initiation point for RNAi within the human cell. The company also develops therapies to treat diseases linking the liver includes rare, viral infections, chronic liver, and cardiovascular diseases. Dicerna is headquartered in Lexington, Massachusetts, the US.
Dicerna Pharmaceuticals Inc premium industry data and analytics
Products and Services
Products |
---|
Nedosiran (formerly DCR-PHXC) |
RG6346 (formerly DCR-HBVS) |
Belcesiran (formerly DCR-A1AT) |
XYZ |
XYZ |
XYZ |
Competitor Comparison
Key Parameters | Dicerna Pharmaceuticals Inc | Arrowhead Pharmaceuticals Inc | Cumberland Pharmaceuticals Inc | Humanigen Inc | Viridian Therapeutics Inc |
---|---|---|---|---|---|
Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
City | Lexington | Pasadena | Nashville | Short Hills | Waltham |
State/Province | Massachusetts | California | Tennessee | New Jersey | Massachusetts |
No. of Employees | 302 | 525 | 85 | 6 | 86 |
Entity Type | Private | Public | Public | Public | Public |
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
J. Kevin Buchi | Chairman | Executive Board | 2019 | 65 |
Douglas M. Fambrough, III | President; Director; Chief Executive Officer | Executive Board | 2020 | 52 |
Douglas Pagan | Chief Financial Officer | Senior Management | 2020 | 49 |
Jim Weissman | Executive Vice President; Chief Operating Officer | Senior Management | 2019 | 59 |
Rob Ciappenelli | Chief Strategy Officer | Senior Management | 2021 | - |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward